Cantor Fitzgerald Lowers Earnings Estimates for CG Oncology

Key Points

• Cantor Fitzgerald has lowered its FY2025 earnings per share estimate for CG Oncology to ($2.19), a decrease from the previous estimate of ($1.83).
• The consensus estimate for CG Oncology's current full-year earnings stands at ($1.31) per share, indicating a broader downward trend in earnings estimates.
• CG Oncology has received a mix of ratings from analysts, with a consensus rating of "Moderate Buy" and a target price averaging $55.30.

CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for CG Oncology in a report issued on Monday, August 11th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($2.19) per share for the year, down from their prior estimate of ($1.83). Cantor Fitzgerald has a "Overweight" rating and a $75.00 price target on the stock. The consensus estimate for CG Oncology's current full-year earnings is ($1.31) per share. Cantor Fitzgerald also issued estimates for CG Oncology's FY2026 earnings at ($3.80) EPS.

CGON has been the subject of several other reports. Royal Bank Of Canada decreased their price objective on shares of CG Oncology from $68.00 to $53.00 and set an "outperform" rating for the company in a research report on Wednesday, July 16th. Morgan Stanley increased their price objective on CG Oncology from $52.00 to $56.00 and gave the company an "overweight" rating in a report on Tuesday, June 17th. The Goldman Sachs Group raised shares of CG Oncology to a "strong-buy" rating and set a $40.00 target price on the stock in a report on Thursday, July 10th. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price target on shares of CG Oncology in a research note on Monday, April 28th. Finally, Scotiabank initiated coverage on CG Oncology in a research note on Wednesday, April 16th. They issued a "sector perform" rating and a $23.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $55.30.

CG Oncology Stock Performance

Shares of CGON stock opened at $24.95 on Wednesday. The stock's fifty day moving average price is $26.20 and its two-hundred day moving average price is $25.56. The company has a market cap of $1.90 billion, a PE ratio of -14.10 and a beta of 0.87. CG Oncology has a fifty-two week low of $14.80 and a fifty-two week high of $40.47.

CG Oncology (NASDAQ:CGON - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.05). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 19.37%.

Institutional Investors Weigh In On CG Oncology

Large investors have recently made changes to their positions in the stock. Winthrop Capital Management LLC purchased a new stake in CG Oncology in the second quarter valued at $38,000. GF Fund Management CO. LTD. purchased a new stake in shares of CG Oncology in the 4th quarter valued at approximately $41,000. CWM LLC boosted its position in shares of CG Oncology by 3,957.7% during the 1st quarter. CWM LLC now owns 2,110 shares of the company's stock worth $52,000 after purchasing an additional 2,058 shares during the period. GAMMA Investing LLC boosted its position in shares of CG Oncology by 1,051.0% during the 1st quarter. GAMMA Investing LLC now owns 2,302 shares of the company's stock worth $56,000 after purchasing an additional 2,102 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of CG Oncology by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company's stock worth $77,000 after purchasing an additional 398 shares during the period. 26.56% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 2,000 shares of CG Oncology stock in a transaction on Thursday, July 17th. The shares were sold at an average price of $28.00, for a total value of $56,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.